Shopping Cart
Remove All
Your shopping cart is currently empty
SR33805 is a potent antagonist of Ca2+ channel(EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively)

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 5 mg | $62 | In Stock | In Stock | |
| 10 mg | $103 | In Stock | In Stock | |
| 25 mg | $188 | In Stock | In Stock | |
| 50 mg | $277 | In Stock | In Stock | |
| 100 mg | $393 | In Stock | In Stock | |
| 200 mg | $537 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $77 | In Stock | In Stock |
| Description | SR33805 is a potent antagonist of Ca2+ channel(EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively) |
| Targets&IC50 | Ca2+ channel, L-type:33 nM (EC50, in polarized conditions), Ca2+ channel, L-type:4.1 nM (EC50, in depolarized conditions) |
| In vitro | Acute treatment with SR33805 restored the MI-altered cell shortening without affecting the Ca(2+) transient amplitude, suggesting an increase of myofilament Ca(2+) sensitivity in MI myocytes.?Indeed, a SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin light chain-2 phosphorylation and a more significant decrease on troponin I (TnI) phosphorylation.?Decreased TnI phosphorylation was related to inhibition of protein kinase A activity by SR33805.?Finally, administration of a single intra-peritoneal bolus of SR33805 (20 mg/kg) improved end-systolic strain and fractional shortening of MI hearts[1] |
| Molecular Weight | 564.74 |
| Formula | C32H40N2O5S |
| Cas No. | 121345-64-0 |
| Smiles | COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)n(C)c3ccccc23)cc1OC |
| Relative Density. | 1.15g/cm3 |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (48.69 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.54 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.